Crovalimab
- Generic Name
- Crovalimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1917321-26-6
- Unique Ingredient Identifier
- H9KH1GP3UU
- Background
Crovalimab is under investigation in clinical trial NCT03157635 (Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria).
- Indication
用于未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症（属罕见病）成人和青少年（≥12岁）患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)
- Conditions
- Guillain-Barré Syndrome
- Interventions
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05494619
A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: CrovalimabDrug: Placebo
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT05075824
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇫🇷CHU Henri Mondor, Créteil, France
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT04958265
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center; Investigational Drug Services, Cincinnati, Ohio, United States
🇮🇳All India Institute Of Medical Sciences (AIIMS), New Delhi, Delhi, India
🇺🇸UT Health Science Center; SouthTexas Pediatric Blood and Cancer Ctr, San Antonio, Texas, United States
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT04912869
- Locations
- 🇺🇸
Children'S Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Michigan; Pediatrics, Detroit, Michigan, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT04861259
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇧🇷UPECLIN Hospital das Clinicas da Faculdade de Medicina de Botucatu, Botucatu, São Paulo, Brazil
🇧🇷Hospital das Clinicas - FMUSP, Sao Paulo, São Paulo, Brazil
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibition
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT04654468
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
🇨🇳Guangdong General Hospital, Guangzhou, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 204
- Registration Number
- NCT04434092
- Locations
- 🇵🇱
MTZ Clinical Research Powered by Pratia, Warszawa, Poland
🇲🇽Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico
🇵🇹Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 190
- Registration Number
- NCT04432584
- Locations
- 🇫🇷
Institut Paoli Calmette; Service d'Hématologie Clinique, Marseille, France
🇬🇷General Hospital of Athens LAIKO, Athens, Greece
🇬🇷Attikon University General Hospital, Chaidari, Greece
Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Paroxysmal Hemoglobinuria, Nocturnal
- Interventions
- Drug: CrovalimabDrug: Placebo
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 59
- Registration Number
- NCT03157635
- Locations
- 🇩🇪
Elblandklinikum Riesa; Klinik fuer Haematologie Onkologie und Gastroenterologie, Riesa, Germany
🇫🇷Institut hematologie Centre Hayem CHU paris Saint-Louis Lariboisiere F Widal Hopital St Louis, Paris, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre Benite, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.